Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis

机译：在转移结直肠癌患者中具有或不含Bevacizumab的含一线含牛肝菌素的治疗的最佳维护策略：Meta分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Maintenance therapy after oxaliplatin withdrawal is useful in patients with metastatic colorectal cancer (mCRC). This study aimed to investigate the timing of discontinuation or reintroduction of oxaliplatin and the optimal maintenance therapy regimen for survival.

机译：oxaliplatin戒断后的维护治疗可用于转移性结肠直肠癌（MCRC）的患者。本研究旨在调查奥沙利铂的停药或重新引入的时间和用于存活的最佳维持治疗方案。

著录项

期刊名称 Cancer Research and Treatment : Official Journal of Korean Cancer Association
作者
Toshikazu Moriwaki; Masahiko Gosho; Akinori Sugaya; Takeshi Yamada; Yoshiyuki Yamamoto; Ichinosuke Hyodo;
展开▼
作者单位

展开▼
年(卷),期 2021(53),3
年度 2021
页码 703–713
总页数 11
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

机译：Bevacizumab;结肠直肠肿瘤;氟嘧啶;维持治疗;荟萃分析;oxaliplatin;生存;

相似文献

外文文献
中文文献
专利

1. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients [J] . European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：用伊立替康/西替昔单抗的治疗序列，然后进行Folfox-4或转移性结肠直肠癌患者的反向策略，在第一线Folfiri / Bevacizumab后进展：用于研究胃肠癌期III的意大利组，随机试验比较两种治疗序列结肠直肠转移性患者
2. Retrospective Analysis of S-1 plus Bevacizumab as Maintenance Therapy after Induction of S-1 and Oxaliplatin (SOX) plus Bevacizumab as First-Line Chemotherapy in Patients with Metastatic Colorectal Cancer [J] . Yasutake Uchima, Naoki Aomatsu, Gen Tsujio, Journal of Cancer Therapy . 2020,第2期

机译：S-1加上贝伐单抗作为诱导S-1和Oxaliplatin（SOX）加上贝伐单抗作为转移结直肠癌患者的一线化疗后的维持治疗
3. Retrospective Analysis of S-1 plus Bevacizumab as Maintenance Therapy after Induction of S-1 and Oxaliplatin (SOX) plus Bevacizumab as First-Line Chemotherapy in Patients with Metastatic Colorectal Cancer [J] . Yasutake Uchima, Naoki Aomatsu, Gen Tsujio, 癌症治疗（英文） . 2020,第002期

机译：转移性结直肠癌患者中S-1联合贝伐单抗作为一线化疗的奥沙利铂（SOX）和贝伐单抗作为一线化疗后维持治疗的回顾性分析
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. New Models of Colorectal Cancer to Facilitate Therapy Development for Metastatic Disease [D] . O'Rourke, Kevin. 2017

机译：新型结肠直肠癌促进转移性疾病治疗的疗效
6. First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study [O] . Eduardo Díaz-Rubio, Auxiliadora Gómez-España, Bartomeu Massutí, 2012

机译：一线XELOX加贝伐单抗继之以XELOX加贝伐单抗或单药贝伐单抗作为转移性结直肠癌患者的维持治疗：III期MACRO TTD研究
7. Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis [O] . Toshikazu Moriwaki, Masahiko Gosho, Akinori Sugaya, 2020

机译：在转移结直肠癌患者中具有或不含Bevacizumab的含一线含牛肝菌素的治疗的最佳维护策略：Meta分析

Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis

摘要

著录项

相似文献

相关主题

期刊订阅